R-CHOP in NLPHL: who should receive it?

摘要

In this issue of Blood, Fanale and colleagues report promising treatment results for patients with newly diagnosed nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) receiving R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) (see figure).